NNRTI

(redirected from nonnucleoside reverse transcriptase inhibitors)
Also found in: Dictionary, Medical.
Related to nonnucleoside reverse transcriptase inhibitors: nucleotide reverse transcriptase inhibitors, Protease inhibitors
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for NNRTI

References in periodicals archive ?
Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Women given the intervention were 53% less likely than controls to have a mutation that conferred resistance to nonnucleoside reverse transcriptase inhibitors at 6 weeks after delivery.
Existing studies of gender-based differences among persons with HIV disease have been conducted before the diffusion of protease inhibitors and nonnucleoside reverse transcriptase inhibitors or immediately thereafter.
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a potent component in salvage therapy.
In addition to the protease inhibitors and the nonnucleoside reverse transcriptase inhibitors (or NNRTIs), new and more powerful second-generation nucleoside analogues (such as lamivudine-3TC) are now also available.
The results will be applied to (the study of) HAART, highly active antiretrovirus therapy based on Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Protease Inhibitors (PIs).
The survey, which looked at specimens from 3,130 newly diagnosed, drug-naive individuals, found that 4% of infections had mutations conferring resistance to nucleoside reverse transcriptase inhibitors, 7% to nonnucleoside reverse transcriptase inhibitors, and 2% to protease inhibitors.
Although the idea of combining three nucleoside reverse transcriptase inhibitors seemed appealing as a way to spare patients some of the toxicities of nonnucleoside reverse transcriptase inhibitors or protease inhibitors, once-daily triple-nucleoside combinations that lacked zidovudine (AZT) often failed because of gene mutations, which were infrequently seen in the past when nearly every regimen contained AZT, investigators reported at the meeting.
They conducted a retrospective chart review from 41 PI experienced patients, which revealed that 73% were also experienced with nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Drug approved: The Food and Drug Administration approves delavirdine, one of a new class of nonnucleoside reverse transcriptase inhibitors.
Currently, the primary classes of HIV drugs are protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Other potential interactions include carbamazepine, protease inhibitors, nonnucleoside reverse transcriptase inhibitors, benzodiazepines, and statins.
Neither nevirapine nor efavirenz emerged victorious in a head-to-head comparison of the safety and efficacy of the two nonnucleoside reverse transcriptase inhibitors in treatment-naive HIV-infected patients.